• 大学概要
  • 学部・大学院
  • 入試・入学
  • キャンパスライフ
  • 進路・就職
  • 附属機関・施設
  • 生涯学習・地域交流

学部・大学院

教員紹介

所属 ヒューマンケア学部 看護学科 教授
氏名 山田 修
最終学歴 東京女子医科大学内科系大学院
現在所属している学会 日本内科学会、日本血液学会、癌学会、東洋医学会、消化器内視鏡学会、超音波学会、臨床内科医会、分子標的治療学会
学士・修士・博士 医学博士
所有資格 医師免許、ECFMG取得、日本内科学会内科専門医、日本東洋医学会認定専門医、日本血液学会専門医・指導医、産業医、がん治療認定医
研究の分野 腫瘍学,腫瘍生物学、臨床腫瘍学
主な研究項目 造血の免疫制御,細胞の老化・不死化と癌化,テロメア・テロメレース
主な研究業績 高久文麿、檀和夫編「私と血液学の仲間たち」 /VISION最新・血液内科シリーズ 2009年/共著/2009.04
私医者に行ったほうがいいですか、-身体の変調に気づいたら読む本- /日本経済新聞出版社 327頁/共著/2010.04
Emergence of a BCR-ABL Translocation in a Patient with the JAK2V617F Mutation: Evidence for Secondary Acquisition of BCR-ACR in the JAK2V617F Clone /Journal of Clinical Oncology/共著/
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents,but not against DNA synthesis inhibitors. /Cancer Lett 2002;178:187-97./共著/2002.04
Xenoantigen,an alphaGal epitope-expression construct driven by the hTERT-promoter,specifically kills human pancreatic cancer cell line. /Cancer Cell Int.2002;3:14-21./共著/2002.05
Thrombocytopenia in patients with 22qll.2 deletion syndrome and its association with glycoprotein Ib-β. /Genitics in Medicine 2003;5:113-19./共著/2003.04
Overxpression of telomerase confers a survival advantage through suppression of TRF1 gene expression while maintaining differentiation characteristics in K562 cells. /Cell Transplant.2003;12:365-77./共著/2003.04
TNF induces rapid activation and nuclear translocation of telomerase in human lymphocytes. /B.B.R.C.2004;316:528-32./共著/2004.04
Transient post-translational up-regulation of telomerase activity during megakaryocytic differentiation of K562 cells. /B.B.R.C.2004;314:1080-85./共著/2004.05
Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-therapy:possible etiology of HCV-associated immune thrombocytopenia. /European Jourmal of Haematology 2005;75:417-23./共著/2005.04
Interleukin-2 increases human telomerase reverse transcriptase activity transcriptionally and post-translationally through phosphatidylinositol 3'-kinase/Akt,heat shock protein 90,and mammalian target of rapamycin in transformed natural killer cells. /Journal of Immunology 2005;174:5261-69./共著/2005.04
Molluscum contagiosum and telomere. /British Medical Journal 2005(Electronic version Jan 29)/共著/2005.05
Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. /Pediatr Blood Cancer.2006;46:506-11./共著/2006.04
Bowen's disease with high telomerase activity. /J Dermatol.2007;34:778-81./共著/2007.04
STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. /Cell Cycle.2007;15:1496-1501./共著/2007.05
Effects of Prednisolone on Specifically Expressed Genes in Pediatric Acute B-lymphoblastic Leukemia. /J Pediatr Hematol Oncol.2008;30:313-16./共著/2008.04
Multistep regulation of telomerase during differentiation of HL60 cells. /Journal of Leukocyte Biology.2008;83:1240-48./共著/2008.04
Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. /Cancer Lett.2008;261:226-34./共著/2008.05
Leukemic Cells with Increased Telomerase Activity Exhibit Resistance to Imatinib. /Leukemia and Lymphoma 2008;49:1168-73./共著/2008.05
Regulation and importance of the PI3K/AKT/mTOR signaling pathway in hematologic malignancies. /Anti-Cancer Agents in Medicinal Chemistry 2009;9:1024-38./共著/2009.04
Antitumor activity of TMPyP4-interacting G-quadruplex in retinoblastoma cell lines. /Experimental Eye Research 2009;89:200-08./共著/2009.05
The PI3K/AKT pathway as a target in the treatment of hematologic malignancies. /Anti-Cancer Agents in Medicinal Chemistry.2009;9:550-59./共著/2009.06
Evaluation of telomerase activity in nongenital Bowen's disease. /Journal of the European Academy of Dermatology and Venerology 2009;23:668-72./共著/2009.07
Akt and PKC are involved not only in upregulation of telomerase acticity but also in cell differentiation-related function via mTORC2 in leukemia cells. /Histochem Cell Biol.2010;134:555-63./共著/2010.04
Combined analysis of cell growth and apoptosis-regulating proteins in HPVs associated anogenital tumors. /BMC Cancer.2010;10:118-28./共著/2010.04
多発性骨髄腫に対するthalidomide療法の効果に関与する因子と効果判定時期 /臨床血液.2010;51:189-95./共著/2010.05
Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. /Cellular Signalling.2011;23:1119-27./共著/2011.04
Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells. /Leukemia Res.2011;35:416-18./共著/2011.04
Telomere長解析と、Telomerase,HER2/neuの発現による甲状腺癌の補助診断 /内分泌外科 2011;28:226-31./共著/2011.05
JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and post-translationally in ATL cells. /Molecular Cancer Therapeutics 2012;11:1112-21./共著/2012.04
Telomeres and telomerase in hematology. /The Journal of Tokyo Women’s Medical University. 2013:83:e520-e538./単著/2013.02
急性骨髄性白血病の分子病態の解析 /癌と化学療法/共著/2013.04
The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies. /JAKSTAT. /共著/2013.10
Biological Differential Diagnosis of Follicular Thyroid Tumor and Hürthle Cell Tumor on the Basis of Telomere Length and hTERT Expression. /Ann Surg Oncol./共著/2014.02
Emergence of a BCR-ABL Translocation in a Patient With the JAK2V617F Mutation: Evidence for Secondary Acquisition of BCR-ABL in the JAK2V617F Clone. /J Clin Oncol./共著/2014.02
(学会発表)ラウンドテーブルディスカッションとIT併用の医学部学生教育への利用 /21年度教育改革IT戦略大会(東京)/共著/2009.09
(学会発表)CML細胞の薬剤耐性とテロメレース /第71回日本血液学会学術集会(京都)/共著/2009.10
(学会発表)MEasurement of telomere length using quantitative PCR in hematologic cells. /第73回日本血液学会学術集会(名古屋)/単著/2011.10
(学会発表)Emergence of CML in a PMF patient with JAK2V617F mutation before therapeutic manopulation. /第74回日本血液学会学術集会(京都)/単著/2012.10
主な担当授業科目名 人体構造学、微生物免疫学、疾病のなりたちと回復の促進、基礎医学I、医学入門

ページの先頭へ


大学の最新情報こちらから請求できます 資料請求 他の学部を調べる 学生生活を見る 入試について知る